Keryx Biopharmaceuticals (KERX) Announces Issuance Of Two U.S. Patents For Zerenex(TM) Covering Orally Administrable Forms Of Ferric Citrate
6/18/2014 8:55:20 AM
NEW YORK, June 18, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) announced today that the U.S. Patent and Trademark Office has issued U.S. Patents No. 8,754,257 and No. 8,754,258. The patents, which expire in 2024, claim pharmaceutical compositions comprising a form of ferric citrate having an intrinsic dissolution rate of 1.88-4.0 mg/cm2/min, and orally administrable forms of ferric citrate prepared from a form of ferric citrate having an intrinsic dissolution rate of at least 1.88/mg/cm2/min, respectively. The active pharmaceutical ingredient (API) of Zerenex is ferric citrate. In addition, U.S. Patent No. 8,754,257 contains claims directed to the dosing and daily administration regimen of Zerenex that is included in the proposed New Drug Application for Zerenex, which is currently under review by the U.S. Food and Drug Administration (FDA).
Help employers find you! Check out all the jobs and post your resume.
comments powered by